Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.92 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.92 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.45 |
| ▸ | FNTB | P49356 | 2/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324537 | 1.00 | PTGS1 (0.92) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL10825773 | 0.97 | PTGS1 (0.88) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL28304097 | 0.97 | PTGS1 (0.88) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL1479109 | 0.97 | PTGS1 (0.88) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL14360534 | 0.97 | PTGS1 (0.88) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL28054046 | 0.96 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL5147539 | 0.96 | PTGS1 (0.95) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL15701576 | 0.96 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL5167025 | 0.96 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL13105609 | 0.96 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893632-B1 | SELECTIVE REDUCTION AND DERIVATIZATION OF ENGINEERED FACTOR VII PROTEINS COMPRISING AT LEAST ONE NON-NATIVE CYSTEINE | NOVO NORDISK HEALTHCARE AG (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8633300-B2 | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine | NOVO NORDISK HEALTHCARE AG (CH) | 2014-01-21 | — | — | US | disclosed |
| EP-1893631-B1 | DIMERIC AND MULTIMERIC FVIIA COMPOUNDS | NOVO NORDISK HEALTHCARE AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| EP-2360170-A2 | Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine | Novo Nordisk Health Care AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| EP-2213733-A2 | Factor IX analogues having prolonged in vivo half life | Novo Nordisk Health Care AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20090252720-A1 | Prolonged FIX Analogues and Derivatives | NOVO NORDISK HEALTH CARE AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2029738-A2 | FACTOR IX ANALOGUES HAVING PROLONGED IN VIVO HALF LIFE | Novo Nordisk Health Care AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20090041744-A1 | Dimeric and Multimeric FVIIa Compounds | NOVO NORDISK HEALTHCARE A/G (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20080200651-A1 | Selective Reduction and Derivatization of Engineered Proteins Comprising at Least One Non-Native Cysteine | NOVO NORDISK HEALTHCARE A/G (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1893631-A2 | DIMERIC AND MULTIMERIC FVIIA COMPOUNDS | Novo Nordisk Health Care AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893632-A2 | SELECTIVE REDUCTION AND DERIVATIZATION OF ENGINEERED PROTEINS COMPRISING AT LEAST ONE NON-NATIVE CYSTEINE | Novo Nordisk Health Care AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007135182-A2 | FACTOR IX ANALOGUES HAVING PROLONGED IN VIVO HALF LIFE | NOVO NORDISK HEALTH CARE AG (DK) | 2007-11-29 | — | — | WO | disclosed |
| WO-2006134174-A2 | DIMERIC AND MULTIMERIC FVIIA COMPOUND | NOVO NORDISK HEALTH CARE AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134173-A2 | SELECTIVE REDUCTION AND DERIVATIZATION OF ENGINEERED PROTEINS COMPRISING AT LEAST ONE NON-NATIVE CYSTEINE | NOVO NORDISK HEALTH CARE AG (CH) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252720-A1 | Prolonged FIX Analogues and Derivatives | FGB, F2, F8 | PTGS1 3569/4885GSTK1 2925/4885GLO1 1134/4885 |
| US-20080200651-A1 | Selective Reduction and Derivatization of Engineered Proteins Comprising at Least One Non-Native Cysteine | PTMS, PDIA6, P4HB | PTGS1 2560/4885GSTK1 23/4885GLO1 26/4885 |
| US-20090041744-A1 | Dimeric and Multimeric FVIIa Compounds | F2, F13B, FGB | PTGS1 2422/4885GSTK1 1327/4885GLO1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.